The potential role of perfluorocarbon emulsions in decompression illness
Bruce D Spiess

Key words
Perfluorocarbons, decompression sickness, decompression illness, air embolism, treatment, research, review article

Abstract
(Spiess BD. The potential role of perfluorocarbon emulsions in decompression illness. Diving and Hyperbaric Medicine. 2010;40:28-33.) Decompression illness (DCI) is an occasional occurrence in sport, professional, and military diving as well as a potential catastrophe in high-altitude flight, space exploration, mining, and caisson bridge construction. DCI theoretically could be a success-limiting problem in escape from a disabled submarine. Perfluorocarbon emulsions (PFCs) have previously been investigated as ‘blood substitutes’ with one approved by the United States Food and Drug Administration for the treatment of myocardial ischaemia. PFCs possess enhanced (as compared to plasma) respiratory gas solubility characteristics, including oxygen, nitrogen and carbon dioxide. This review examines approximately 30 years of research regarding the utilization of PFCs in gas embolism as well as experimental DCI. To date, no humans have been treated with PFCs for DCI.

Introduction
Decompression illness (DCI) is an incompletely defined clinicopathological diagnosis in humans with a wide spectrum of presenting signs and symptoms.1,2 The disease is caused by gas bubble formation/movement in tissues and within the vascular tree or by gas forced into the circulation from pulmonary barotrauma. These gas bubbles cause either primary direct tissue destruction or secondary events from decreased blood flow (oxygen delivery), endothelial cell dysfunction, inflammation, coagulopathy/thrombosis and many other effects. The readership is familiar with many of the manifestations and difficulties with the diagnosis of DCI and is referred elsewhere for review.1–3

Mankind lives and works most often in a narrow range of ambient gas pressures. The gas column above us functions as a fluid, exerting continuous equal pressure to all parts of the body. Gases are soluble in tissues and blood, based upon Henry’s law. At 101.3 kPa (1 bar) the human body is saturated, with all respiratory gases in equilibrium with the partial pressures of each gas. Seventy per cent of the body is made up of water, therefore the relative solubility coefficients for respiratory gases in water versus fat (oils) determine the total amount of gas dissolved in aqueous media or tissues at any one time.4,5 It is through a sudden decrease in ambient pressure that tissues and blood potentially become supersaturated with gases. Supersaturation leads to bubble formation. The respiratory gases leave their dissolved state when some, as yet undefined, parameter allows for a small nidus of micro-bubble formation to occur.6 It has been suspected that micro-particles allow for the original formation of micro-bubbles.6 Once formed the micro-bubbles grow, potentially rapidly, as local, supersaturated gases move from tissue and blood into the gaseous phase of the micro-bubble.

Growth of a bubble is dependent upon gas composition, internal/external pressures and the surface tension of the bubble itself.6 Bubble dynamics is an entire study unto itself, but, suffice to say, particularly within the blood stream, bubbles are rapidly coated with proteins that themselves then have complex interactions with tissues, cells and the micro-environment.6–7 DCI is often thought to be a disease of diving, with inadequate times for gas equilibration between various faster and slower equilibrating tissue categories. However, any rapid reduction in ambient pressure may cause DCI and as man ventures into ever more unique
environments (deep ocean, high altitude and space) the potential for DCI will be ever more challenging.

To date, the standard of care has been to treat suspected DCI with high inspired oxygen (O\textsubscript{2}) and, as rapidly as possible, with recompression therapy.\textsuperscript{2,8} Recompression therapy requires specialized, expensive, bulky, not easily transported equipment, as well as trained personnel. Transport from remote accident/dive sites to an available treatment chamber may require many hours, involve difficult logistics and therein further delay treatment, as well as altitude exposure during air transport. A robust, easily administered, effective, non-toxic therapy that could begin as soon as DCI was suspected would, therefore, represent a dramatic advance in treatment. The remainder of this article will explore work performed to offer a potential alternative/supplement to existing recompression therapy.

Prior PFC studies

Perfluorocarbons are organic-based oils that have complete substitution of the carbon hydrogen bonds with fluoride.\textsuperscript{9,10} Respiratory gases are non-polar molecules whereas water is a highly polar molecule. The gas solubility coefficient for gases is dependent upon relative polarity between the gas and the solution as well as molecular size. Organic fluids, for example fats such as membranes, have a higher solubility coefficient for respiratory gases than water. Plasma (60% of blood) is water-based, with some proteins and fat micelles. Blood supplies O\textsubscript{2} to cells through a complex interaction of erythrocytes (acting as an O\textsubscript{2} bank) and dissolved O\textsubscript{2} in plasma. Nitrogen (N\textsubscript{2}) and other insoluble gases have a limited capability of being carried in blood and plasma. PFCs, because of their change in molecular polarity, change gas solubility dramatically. PFCs have a 50- to 60-fold enhanced O\textsubscript{2} solubility as compared to aqueous media. Their ability to dissolve N\textsubscript{2} may be even greater. The use of PFC emulsions (stable intravenous solutions) offers an attractive possibility for the treatment/prevention of DCI. The preceeding article in this issue describes how PFCs act as gas transporters.\textsuperscript{11}

Early work with PFC emulsions utilized a relatively weak (less concentrated) set of emulsions. FC-43 and Fluosol-DA 20% were 10\% v-v of PFC as compared to solutes and emulsifying agents. Fluosol-DA 20\%, a Japanese-manufactured emulsion, was the first ‘blood substitute’ FDA-approved PFC for human usage.\textsuperscript{12} FC-43 had a longer half-life and was utilized for animal studies only. These were investigated in the 1970s and 80s as potential ‘artificial blood’ compounds. A series of cases of use in humans of Fluosol-DA 20\% for patients refusing blood transfusion was heralded and its usage for coronary ischemia made it commercially available.\textsuperscript{13} The emulsion itself was cumbersome (supplied frozen and not completely emulsified) and for that reason it was withdrawn from the market in 1994.

In DCI, the earliest work was in rodent models.\textsuperscript{13-15} Work in hamsters and rats showed that the use of these agents could potentially prolong life after usually lethal experimental dives. Neither of the groups that did the early work in these rodent models followed up with larger animal models or proposed going to human trials. This initial success did spur other work, but the focus was more on arterial gas embolism (AGE) in heart surgery than on the treatment of DCI in dive accidents.

Treatment of venous (femoral vein) gas embolism (VGE) in rabbits was investigated as a model of surgical gas embolism prevention, and provided early experimental evidence that PFCs could perhaps absorb air.\textsuperscript{16} In both continuous (0.25ml kg\textsuperscript{-1} min\textsuperscript{-1}) and bolus air embolism models, the instillation of FC-43 dramatically prolonged life in 100\% O\textsubscript{2}-breathing animals. Both venous and arterial partial pressures of O\textsubscript{2} were better in the PFC groups, whilst central venous pressure was lower in the PFC, O\textsubscript{2}-breathing group, suggesting partial resolution of bubble size. In the PFC group breathing room air, the average time to death was the same as in those who did not receive PFC. Of interest, that particular PFC emulsion was stabilized by a unique emulsifier. The use of emulsifier alone did not enhance prolongation of survival.\textsuperscript{16} Other studies using larger animal AGE and VGE models showed promise in terms of prevention of organ damage (stroke and myocardial infarction as well as death).\textsuperscript{17-20}

An awake-rat, DCI survival study with compression to 690 kPa (6.8 bar) for a short bottom time also demonstrated that PFC infusion immediately after surfacing, but prior to the full development of DCI, dramatically decreased lethality by 24 hours (control 11/12 versus PFC 4/12).\textsuperscript{21} The numerical reduction in lethality is not the entire story. Those that died of DCI in the untreated group did so very quickly whereas even those that did die of DCI after PFC treatment and 100\% oxygen breathing did so much later in their time course. These first rodent experiments were focused on the efficacy of PFCs for a much more prevalent problem, AGE and VGE in surgery, particularly cardiac surgery, rather than on DCI.

A model of gas saturation in muscle tissue examined radioactive xenon washout. Xenon is an inert and relatively insoluble gas.\textsuperscript{22} Dogs were allowed to breathe radioactive xenon until such time as they had saturated all their striated muscle tissues. They were then given either a saline control volume expander or an equal volume of PFC emulsion and the speeds of off-gassing of the xenon and muscle washout were examined. It was calculated that, given the dose of the PFC utilized, its relative amount in a stable emulsion, volume of distribution, etc, that the speed of muscle removal of xenon would be increased by 77\%. In actuality the speed of xenon washout exceeded that and was increased 109\%. It should be noted that this did not come anywhere near a 30- to 50-fold increase in solubility that could be calculated for xenon in pure PFC alone. However, because the amounts of PFC in stable emulsions are limited and the amount of
emulsion added to the circulating volume is again limited, the washout speeds achieved are more modest.

The findings of PFC-enhanced survival after experimental air-dive DCI went under-appreciated for about a decade. In the late 1990s, the PFC literature was reviewed and a large animal (swine) saturation dive model with >85% lethality perfected. These investigators had used this dive profile as a standardized tool with which to investigate a number of interventions. The United States Navy, in developing this large swine model, has utilized it as a more reliable reflection of human physiology than rodent models. In a now landmark study, 20–25 kg swine were compressed to 485 kPa (4.8 bar) for 22 hours (thought to be a N₂ saturation dive). From that depth, they were rapidly decompressed (202.6 kPa min⁻¹). The day prior to diving, the swine had an indwelling catheter placed for intravenous or PFC infusion after surfacing. Upon surfacing, the animals were immediately removed from the chamber and placed in plastic cages breathing either room air or ≥ 95% O₂. Three groups were studied: a control group which received volume expansion but breathed room air; another group with volume expansion and enhanced O₂ and the experimental group which received 6 ml kg⁻¹ of PFC (Oxygent™, Alliance Pharmaceuticals Inc, San Diego, California) within 10 minutes of emergence. The results were dramatic, with a reduction in lethality from 85% to 15%. Of interest, this reduction in lethality was similar to that seen in the rodent model, has utilized it as a more reliable reflection of human physiology than rodent models. In a now landmark study, 20–25 kg swine were compressed to 485 kPa (4.8 bar) for 22 hours (thought to be a N₂ saturation dive). From that depth, they were rapidly decompressed (202.6 kPa min⁻¹). The day prior to diving, the swine had an indwelling catheter placed for intravenous or PFC infusion after surfacing. Upon surfacing, the animals were immediately removed from the chamber and placed in plastic cages breathing either room air or ≥ 95% O₂. Three groups were studied: a control group which received volume expansion but breathed room air; another group with volume expansion and enhanced O₂ and the experimental group which received 6 ml kg⁻¹ of PFC (Oxygent™, Alliance Pharmaceuticals Inc, San Diego, California) within 10 minutes of emergence. The results were dramatic, with a reduction in lethality from 85% to 15%. Of interest, this reduction in lethality was similar to that seen in the rodent experiments. Of great interest was the observation that any animals that did succumb in the PFC-treated group died a sudden death. Such animals were up and around their enclosures walking, eating and drinking normally then suddenly collapsed and died as though an air embolism had obstructed a coronary artery. Those who breathed room air or O₂ succumbed to neurological (ataxia and paralysis) and obstructed a coronary artery. Those who breathed room air suddenly collapsed and died as though an air embolism had enclosures walking, eating and drinking normally then a sudden death. Such animals were up and around their experiments. Of great interest was the observation that any reduction of lethality was similar to that seen in the rodent model, has utilized it as a more reliable reflection of human physiology than rodent models. In a now landmark study, 20–25 kg swine were compressed to 485 kPa (4.8 bar) for 22 hours (thought to be a N₂ saturation dive). From that depth, they were rapidly decompressed (202.6 kPa min⁻¹). The day prior to diving, the swine had an indwelling catheter placed for intravenous or PFC infusion after surfacing. Upon surfacing, the animals were immediately removed from the chamber and placed in plastic cages breathing either room air or ≥ 95% O₂. Three groups were studied: a control group which received volume expansion but breathed room air; another group with volume expansion and enhanced O₂ and the experimental group which received 6 ml kg⁻¹ of PFC (Oxygent™, Alliance Pharmaceuticals Inc, San Diego, California) within 10 minutes of emergence. The results were dramatic, with a reduction in lethality from 85% to 15%. Of interest, this reduction in lethality was similar to that seen in the rodent experiments. Of great interest was the observation that any animals that did succumb in the PFC-treated group died a sudden death. Such animals were up and around their enclosures walking, eating and drinking normally then suddenly collapsed and died as though an air embolism had obstructed a coronary artery. Those who breathed room air or O₂ succumbed to neurological (ataxia and paralysis) and cardiopulmonary DCI (pulmonary oedema and tachypnoea). Thus, not only was there a quantitative difference in lethality, but also a clear difference in the physiological path leading to death.

Other work in AGE had shown that PFCs infused to a cardiopulmonary bypass (CPB) machine prior to either routine CPB or a massive cerebral AGE could dramatically reduce the effects of embolism. AGE is a near-universal event in CPB for heart surgery. Massive AGE, however, is a rare and devastating event, whereas micro air emboli happen in every case. Retinal angiography has shown that temporary occlusion of arterioles occurs in most CPB cases and that by 45 minutes after surgery these occlusions have passed. With a first-generation PFC infusion in dog models of CPB, up to 95% of the microvascular obstructions from AGE could be prevented. In the massive air embolism model, PFC infusion prior to AGE prevented cerebral strokes, attenuated electroencephalographic insult and actually increased brain blood flow. Furthermore, in some unique studies of retinal endothelial permeability after AGE, it was shown that, by using PFC prior to an AGE, endothelial integrity could be maintained. Clearly PFC pre-treatment protected the vasculature from the effects of transiting air. Later work examining present-day PFCs and isolated, cultured endothelial cells has supported this earlier CPB work. Other research has shown that PFC given prior to AGE decreases a bubble’s dwell time in the pre-capillary arterioles. Furthermore, they have shown that air bubbles, when touched to the cell membrane of cultured endothelial cells, will cause a programmed cell death for those cells. In the presence of PFC, this effect of killing endothelial cells is largely prevented for reasons that are still not clear. Eckmann has also shown that bubble dissolution time is sped up when PFC is present in the microcirculation. This work was conducted using a Russian PFC formulation very similar to the weak, first-generation FC-43 and Fluosol-DA 20%.

Essentially the work by Dromsky et al could be viewed as either pre-treatment or very early treatment/prevention of DCI. The swine, when surfaced immediately, received intravenous PFC. The AGE and VGE experiments were carried out with the same idea of pre-treatment. In a series of studies trying to understand the physiology of PFC, VGE and DCI models in rabbits and then in swine were utilized. In these experiments, animals were highly instrumented and mechanically ventilated. The respiratory exhaled gases were continuously monitored with a mass spectrometer recording breath by breath end-tidal N₂ concentrations. In the rabbit study with PFC pre-treatment and VGE carried out in exactly the same manner as the work from the early 1980s, those animals that had PFC introduced into their circulation had a higher peak exhaled N₂ and a quicker return to baseline (no detectable N₂, Figure 1). It is interesting to note that, with PFC present, prior to femoral vein air embolism, there exists a small but noticeable amount of N₂ coming out of the animal. This may be due to enhanced N₂ tissue washout because the PFC is stored in its vials with argon gas, not N₂. The conclusion was that PFC partially increased the speed of N₂ elimination through the lungs.

In a swine DCI project, highly instrumented anesthetized, spontaneously breathing animals were dry dived to 608 kPa (6 bar) for 30 minutes bottom time. On surfacing, severe cardiopulmonary DCI developed. Animals were treated with PFC immediately upon removal from the dive chamber and then underwent controlled ventilation with 100% O₂. Although outwardly this study had some similarities to the earlier US Navy work (swine and treatment at surface), it had major differences (spontaneous versus controlled ventilation, anesthetized versus awake, and fully instrumented) and was pursued in an attempt to further understand the physiology of PFC in DCI. Those animals which received PFC had a slightly faster N₂ washout. At necropsy, most of the animals had large bubble loads still present in their pulmonary arteries and right heart, suggesting that even though the mass spectrometer had detected washout of N₂ DCI was very much present. The swine study showed that the creation of bubbles in the venous circulation was greatly reduced when PFC was present.
(Figure 2). Control saline is simply a measure of background noise, in that these animals did not undergo DCI. A new bubble-counting technology (EDAC, Luna Technologies, Hampton Roads, VA, USA) had been applied to the internal jugular vein. Using active sonar, this technology counts and can potentially characterize bubble size as emboli move past the sensor. This provides more quantitative information than standard ultrasound detectors. So, although both mass spectroscopy and the bubble-counting device showed promise in terms of the physiologic effects of PFC to blunt the response, the cardiac output and pulmonary artery pressures rose in the animals that received PFC. Swine have a species-specific pulmonary hypertensive response to the micro-particles of the PFC emulsion. This had been well described elsewhere but considerably confused the data. Even with that effect, there was a positive survival effect of PFC as has been the case in all the other, both large and small, animal studies.

Because of the pulmonary vascular effect in swine, the next series of experiments switched to sheep, as they had little or certainly much less of a pulmonary vascular hypertensive response. Again, changes in exhaled N<sub>2</sub> were seen, but more important seemed to be the effects of whole-body O<sub>2</sub> delivery and utilization. Although N<sub>2</sub> washout curves were similar, the plateau that the animals reached showed more total N<sub>2</sub> removed in the PFC group. In animals that received the intravenous emulsion and breathed a helium-O<sub>2</sub> mixture, there was a slightly increased removal of N<sub>2</sub>. The most important finding of this work was not the amount or speed of N<sub>2</sub> washout, but that animals with PFC had an increased O<sub>2</sub> delivery to tissues and an increased O<sub>2</sub> utilization. The conclusion was that there is a combined effect of PFC in DCI, both decreasing bubble effects and, perhaps more importantly, increasing O<sub>2</sub> delivery to tissues at risk for ischemia.

The US Navy laboratories have continued working with their awake-swine, saturation-dive model of DCI. In an effort to ‘prevent’ DCI, PFC was given at depth ten minutes prior to surfacing. Results for PFC given at depth were compared to those with PFC given on surfacing, as well as for a 10-minute period of 100% O<sub>2</sub> pre-breathing prior to rapid surfacing (Figure 3). Both O<sub>2</sub> pre-breathing and PFC infusion at depth were better than no treatment, but the best was treatment at the surface with PFC and 100% O<sub>2</sub>. What was missing from this study was a combination of O<sub>2</sub> pre-breathing and PFC at depth as well as O<sub>2</sub> breathing during the surfacing time period.

Breathing a high O<sub>2</sub> partial pressure combined with an enhanced O<sub>2</sub>-carrying capacity and tissue delivery of O<sub>2</sub> carries the possibility of seizures at depth. It appears that concern is warranted. When the same group investigated grand mal seizure activity at 507 kPa (5 bar) with control versus saline infusion versus PFC infusion, they noted 0/26 seizures in the controls, 1/16 in the saline-infusion group and 7/16 in the PFC-infusion group. In this study, all animals...
breathed an enhanced \( \text{O}_2 \) mixture (46\% \( \text{N}_2 \), 54\% \( \text{O}_2 \)). Even with these problems, there was no increase in death rate due to PFC. Indeed, PFC animals had the best survival statistics. Does this mean that DCI cannot be prevented with PFC at depth? To date, there has been no trial using other gas mixtures at depth with controlled levels of \( \text{O}_2 \), and perhaps helium as an inert gas for pre-breathing prior to assent along with PFC infusion. Also, it cannot be assumed that DCI victims who have previously received PFC infusions could not be recompressed.

**Future research directions**

Some key pieces of information remain to be investigated before PFC infusion, in conjunction with high \( \text{FiO}_2 \) breathing, can be recommended as an adjunctive or non-recompression treatment for DCI. If PFC were to be utilized, it is most likely that it would be utilized first in a group of victims who have a delayed or prolonged travel time to definitive recompressive therapy. That would make sense, in that the PFC treatment is portable and easy to administer, as is \( \text{O}_2 \) therapy. However, a major question remains in terms of how long after symptoms develop does PFC therapy retain efficacy? That question is now being investigated by the US Navy and our laboratory. If, for example, spinal cord AGE was encountered and symptoms had been present for 12–24 hours, would PFC infusion still be able to provide any central neurologic salvage? If a victim receives PFC and then either does not have complete resolution of their symptoms or develops symptoms later, could they safely be recompressed using a standard 284 kPa compression dive table? This question, and any increased risk in seizure activity, is presently being investigated.

A major challenge to regulatory approval of PFC therapy for DCI is the fact that it is essentially unethical to create experimental DCI in humans for the purpose of a randomized treatment trial. The groups working in this area have held discussions with the US FDA to invoke a ‘two-animal rule’ for approval of a new drug indication. This rule allows for proving efficacy with more than one species using the prescribed treatment, i.e., PFC intravenous infusion at the surface with enhanced \( \text{O}_2 \) breathing. Still, safety needs to be proven. If a DCI indication is allowed by regulatory agencies, the safety of the drug infusion will have to be proven both in human volunteers (divers at surface without DCI) and other human trials (traumatic brain injury trials, for example, wherein PFC treatment is underway).

**Conclusions**

There is considerable literature and scientific support for the use of a PFC intravenous infusion in conjunction with 100\% \( \text{FiO}_2 \) breathing to treat/prevent DCI. Although the work has spanned nearly 30 years of animal experimentation, no human has yet to be treated for DCI with PFC. To do so safely today remains as yet unethical, since we do not know the consequences of such treatment in terms of limiting standard treatment options. However, groups are working today on answering the remaining questions and the data from such studies look promising in terms of being able to recompress victims without undue risk of seizures. Perhaps in the not too distant future, PFC infusions could be utilized at the site of first contact/rescue when an intravenous line is placed to begin treatment prior to transport and recompression therapy.

It may well be possible and ethically appropriate to design a human trial of such therapy in a sub-group of patients for whom lengthy transport or delays to treatment are expected. Only once more is known about recompression with PFC circulating will it be possible to push the possibilities of human trials and/or change recompression tables depending upon \( \text{N}_2 \) off-gassing and alternative gas-mixture breathing. One motivation for developing PFC treatment of DCI is disabled submarine rescue, wherein a potential mass casualty event with DCI is at least a theoretical fear. PFC appears promising as a therapeutic option in such a disaster scenario, wherein it would be logistically difficult to have enough chambers and trained personnel on site at a DISSUB rescue mission. This is most likely to happen in remote parts of the world with politically difficult or hostile environments meaning that quick movement of medical teams and rescue vehicles into position may be difficult or impossible. Therefore PFC as a pre-treatment or early intervention at 101.3 kPa appears, at least scientifically, at this point to hold great promise.

**Grant acknowledgment**

Financial support has been received from the United States Office of Naval Research for some of the author’s research which is quoted in this manuscript. ONR Grants: # N000140810459, N000140810474, N000140810366.

**Disclosure**

The author discloses that he has received research money and consulting fees from HemaGen Inc, St. Louis, Mo.; Alliance Pharmaceuticals, San Diego, CA; Oxygen Biotherapeutics Inc, Durham, NC. The author serves on the Board of Directors of Oxygen Biotherapeutics for which he is compensated and has equity interests. Virginia Commonwealth University holds patents and other intellectual property with regard to perfluorocarbon emulsions, topical usage and adjunctive therapies that Oxygen Biotherapeutics has licensed from VCU. The author is a co-inventor on some of these patents and receives royalties.

**References**


Submitted: 17 September 2009
Accepted: 15 October 2009

Bruce D Spiess, MD, FAHA, is Professor of Anesthesiology and Emergency Medicine and Director of Virginia Commonwealth University Reanimation Engineering Shock Center (VCURES). He was the Guest Speaker at the SPUMS ASM 2010, Vanuatu.

Address for correspondence:
1101 East Marshal Street
Sanger Hall B1-007
Virginia Commonwealth University Medical Center
Richmond, Virginia 23298-0695, USA
E-mail: <BDspiess@hsc.vcu.edu>